Alpha-Lipoic Acid for Diabetic Neuropathy and Blood Sugar: What Trials Found
What randomized trials and reviews found for alpha-lipoic acid in diabetic nerve symptoms and blood sugar, by oral and IV route, and why the evidence is rated mixed.
Content last updated . This page has not been medically reviewed.
Quick answer
For painful or tingling feet in diabetes, reviews of alpha-lipoic acid trials show some symptom improvement, but results differ by route (by mouth or IV), outcome measured and study quality. For blood sugar, reviews disagree and the average changes were small. NCCIH, the US government's complementary health agency, summarizes it as weak evidence of a possible benefit for neuropathy pain, with no clear conclusion because studies differ in size, formulation, dosing and length. [1] This is general information, not a treatment plan: new numbness, burning or pain needs a medical assessment, and diabetes treatment is directed by your own clinician.
How the terms are used
- Diabetic neuropathy is nerve damage caused by diabetes. [1]
- Total symptom score (TSS) is a questionnaire of stabbing pain, burning pain, tingling and numbness of the feet. [2]
- Nerve conduction velocity is a lab measurement reported in the IV trials. [3] A better test result is not the same as feeling better.
- Alpha-lipoic acid (ALA) here means lipoic acid, not omega-3 alpha-linolenic acid; see alpha-lipoic acid.
What the trials and reviews found
| Question | What the source found | Strength of evidence |
|---|---|---|
| Does ALA by mouth ease symptoms? (one trial) | In SYDNEY 2, 181 people with diabetic neuropathy in Russia and Israel took 600, 1,200 or 1,800 mg or placebo once daily for 5 weeks; all three ALA groups improved symptom scores more than placebo. [2] | Promising but limited (one 5-week trial; study amounts) |
| Does ALA by mouth work across trials? | A 2023 meta-analysis of 10 randomized trials (1,242 patients) found better total symptom scores (a dose-related trend) and global satisfaction, but ALA did not produce favorable results for VAS pain, vibration threshold, NIS-LL or nerve conduction. [4] | Mixed |
| Is the evidence consistent? | NCCIH cites a 2022 review of 8 studies: 3 found symptom improvement and 5 did not. [1] | Mixed |
| Does IV ALA help? | A meta-analysis of 15 trials (300 to 600 mg IV a day for 2 to 4 weeks) found better nerve conduction and symptoms, but most trials had poor methodological quality. [3] | Promising but limited |
| Does ALA lower HbA1c and fasting glucose? | A meta-analysis of 41 articles found lower HbA1c and fasting glucose, with no effect on insulin or insulin resistance. [5] | Mixed |
| Are those changes meaningful? | A dose-response analysis of 16 trials (1,035 patients with type 2 diabetes) found the effects of oral ALA were below minimal clinically important difference thresholds. [6] | Mixed |
| Is it better than placebo for blood sugar? | NCCIH cites a 2019 review of 10 studies (553 participants) in which ALA was no better than placebo for blood sugar, cholesterol or triglycerides. [1] | No good evidence of benefit |
| Eye or kidney complications? | NCCIH cites a 2-year, 467-person trial with no significant difference in diabetic macular edema, and a review where kidney function did not improve. [1] | No good evidence of benefit |
Do not carry results across forms. IV results are not oral results, and SYDNEY 2 compared oral amounts in one population for 5 weeks. A better nerve test is a biomarker; symptom scores and quality of life are clinical outcomes.
Clinical use in other countries
A 2004 critical review described intravenous thioctic acid (another name for lipoic acid) as a drug studied in diabetic neuropathy trials, with 3 weeks of IV treatment at 600 mg a day reported to reduce the chief symptoms. [7] Which countries approve it as a medicine, and for what, is not described in the sources we read, so we make no claim about licensing. If a clinician prescribes or administers it, follow their directions.Frequently asked questions
Does alpha-lipoic acid cure diabetic neuropathy?
No source we read says so. Reviews describe symptom improvement in some trials and not others. [4][1]
Is IV alpha-lipoic acid better than capsules?
The IV and oral trials differ in design and quality, so they cannot be directly compared. IV results came mostly from poor-quality trials. [3]
Does it lower blood sugar?
Reviews disagree, and one found the average changes too small to be clinically important. [5][6]
How long do the trials last?
SYDNEY 2 lasted 5 weeks and the IV trials 2 to 4 weeks. [2][3] Long-term effects are not established.
Can I use it instead of my diabetes medicine?
No. NCCIH warns against replacing medical treatment for diabetes. [1] Talk to your prescriber before changing anything.
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Limits and uncertainty
- Most trials are short (weeks), so long-term nerve protection is unknown: a review's own conclusion is that using ALA to prevent neurological symptoms should be further researched. [4]
- Many included trials were of poor quality. [3][5]
- Proper evidence not found, in the sources we read, for multi-year nerve outcomes (we searched PubMed and the NCCIH diabetes fact sheet).
Safety and who should ask a clinician
- Side effects: nausea, vomiting and vertigo rose with dose in SYDNEY 2. [2]
- Low blood sugar: ALA has been linked to rare cases of insulin autoimmune syndrome. [8] See side effects, interactions and low blood sugar cautions.
- Do not replace diabetes care: NCCIH warns against replacing medical treatment for diabetes with an unproven product. [1] Your prescriber decides about any change to medicines.
- Ask a clinician or pharmacist first if you are pregnant, breastfeeding, have kidney or liver conditions, take other medicines, or have surgery planned. See medication interactions and existing conditions.
Related: diabetes and metabolic health, antioxidants and medicines including diabetes drugs.
References
- Diabetes and Dietary Supplements: What You Need To Know. National Center for Complementary and Integrative Health (US). Read 2026-10-22.
- Ziegler D, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006. Read 2026-10-22.
- Han T, et al. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 2012. Read 2026-10-22.
- Hsieh RY, et al. Effects of oral alpha-lipoic acid treatment on diabetic polyneuropathy: a meta-analysis and systematic review. Nutrients 2023. Read 2026-10-22.
- Rahimlou M, et al. Alpha-lipoic acid (ALA) supplementation effect on glycemic and inflammatory biomarkers: a systematic review and meta-analysis. Clin Nutr ESPEN 2019. Read 2026-10-22.
- Jibril AT, et al. Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose-response meta-analysis of randomized trials. Endocr Connect 2022. Read 2026-10-22.
- Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol 2004. Read 2026-10-22.
- Vallianou NG, et al. Alpha-lipoic acid as a trigger of insulin autoimmune syndrome: current evidence, a case-based approach, diagnostic pitfalls, and practical management. Metabol Open 2026. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.